Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Novartis's Entresto Doesn't Impress In 1Q; Orphan Drug Fails In PhIII

This article was originally published in Scrip

Executive Summary

Novartis AG's newly launched heart failure drug Entresto (valsartan/sacubitril), which has been dubbed the company's next blockbuster product, missed the mark in the first quarter of the year, posting sales more than $10m below analyst forecasts.

You may also be interested in...



Entresto US Sales Barriers Set To Be Removed By Strong Guidance

Sales prospects for Novartis AG's struggling Entresto have been boosted – especially in the US – by new global cardiology guidelines issued by three organizations containing stronger than expected recommendations for its use in treating heart failure.

AstraZeneca Groomed Paul Hudson For His New Role … At Novartis

Ten years at AstraZeneca PLC have prepared US President and Executive Vice President of North America Paul Hudson for his next C-suite job, but unfortunately for his current employer that gig is with a major competitor – Novartis AG.

Novartis's Entresto Clears NICE But It’s a Close Run Thing

The innovative nature of Novartis's new chronic heart failure therapy Entresto counted towards NICE's appraisal committee clearing its use in Britain's National Health Service, despite a cost-effectiveness ratio that was close to the upper limit for gaining a positive recommendation.

Topics

Latest News
See All
UsernamePublicRestriction

Register

SC065009

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel